Here's Why the Next 4 Months May Be Critical for Pfizer
(NYSE: PFE) offered investors certainty in the earlier stages of the pandemic. People were clamoring for coronavirus vaccines and treatments, and Pfizer became a leader in both markets. Its Comirnaty vaccine and its antiviral treatment Paxlovid brought in billions of dollars in sales and helped Pfizer reach $100 billion in annual revenue -- a record high -- last year.
Since, though, the certainty of demand for those products has turned to uncertainty. As we head toward a post-pandemic situation, people aren't rushing out to get coronavirus vaccines and boosters at the same rate as before. It's still too early to feel comfortable about making estimates of the level of annual demand we'll see for those vaccines and treatments in the years to come.
We soon may understand a lot more about the future coronavirus market, though, and the next four months may be particularly critical for Pfizer.
Source Fool.com
Pfizer Inc. Stock
The stock is one of the favorites of our community with 31 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 55.27% compared to the current price of 26.41 € for Pfizer Inc..
